Prophylactic and therapeutic vaccination against hepatitis C virus (HCV): Developments and future perspectives

Viruses

Volumn 1, Issue 2, 2009, Pages 144-165

  Major, Marian E ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Immune responses; Immunotherapy; Neutralizing antibody; T cells; Vaccine

Indexed keywords

EID: 82355188723     PISSN: 19994915     EISSN: None     Source Type: Journal    
DOI: 10.3390/v1020144     Document Type: Review

References (121)

1. Bartenschlager, R.; Frese, M.; Pietschmann, T. Novel insights into hepatitis C virus replication and persistence. Adv. Virus Res. 2004, 63, 71-180.
2. Moradpour, D.; Penin, F.; Rice, C.M. Replication of hepatitis C virus. Nat. Rev. Microbiol. 2007, 5, 453-463.
3. Alter, M.J.; Kruszon-Moran, D.; Nainan, O.V.; McQuillan, G.M.; Gao, F.; Moyer, L.A.; Kaslow, R.A.; Margolis, H.S. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N. Engl. J. Med. 1999, 341, 556-562.
4. Liang, T.J.; Rehermann, B.; Seeff, L.B.; Hoofnagle, J.H. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann. Intern. Med. 2000, 132, 296-305.
5. Hoofnagle, J.H. Course and outcome of hepatitis C. Hepatology 2002, 36, S21-S29.
6. Manns, M.P.; McHutchison, J.G.; Gordon, S.C.; Rustgi, V.K.; Shiffman, M.; Reindollar, R.; Goodman, Z.D.; Koury, K.; Ling, M.; Albrecht, J.K. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358, 958-965.
7. Fried, M.W.; Shiffman, M.L.; Reddy, K.R.; Smith, C.; Marinos, G.; Goncales, F.L., Jr.; Haussinger, D.; Diago, M.; Carosi, G.; Dhumeaux, D.; Craxi, A.; Lin, A.; Hoffman, J.; Yu, J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 2002, 347, 975-982.
8. Simmonds, P.; Bukh, J.; Combet, C.; Deleage, G.; Enomoto, N.; Feinstone, S.; Halfon, P.; Inchauspe, G.; Kuiken, C.; Maertens, G.; Mizokami, M.; Murphy, D.G.; Okamoto, H.; Pawlotsky, J.M.; Penin, F.; Sablon, E.; Shin, I.; Stuyver, L.J.; Thiel, H.J.; Viazov, S.; Weiner, A.J.; Widell, A. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005, 42, 962-973.
9. Mizushima, H.; Hijikata, M.; Tanji, Y.; Kimura, K.; Shimotohno, K. Analysis of N-terminal processing of hepatitis C virus nonstructural protein 2. J. Virol. 1994, 68, 2731-2734.
10. Weiner, A.J.; Brauer, M.J.; Rosenblatt, J.; Richman, K.H.; Tung, J.; Crawford, K.; Bonino, F.; Saracco, G.; Choo, Q.L.; Houghton, M. Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins. Virology 1991, 180, 842-848.
11. Sekiya, H.; Kato, N.; Ootsuyama, Y.; Nakazawa, T.; Yamauchi, K.; Shimotohno, K. Genetic alterations of the putative envelope proteins encoding region of the hepatitis C virus in the progression to relapsed phase from acute hepatitis: humoral immune response to hypervariable region 1. Int. J. Cancer 1994, 57, 664-670.
12. Major, M.E.; Feinstone, S.M. The molecular virology of hepatitis C. Hepatology 1997, 25, 1527-1538.
13. Taniguchi, S.; Okamoto, H.; Sakamoto, M.; Kojima, M.; Tsuda, F.; Tanaka, T.; Munekata, E.; Muchmore, E.E.; Peterson, D.A.; Mishiro, S. A structurally flexible and antigenically variable Nterminal domain of the hepatitis C virus E2/NS1 protein: implication for an escape from antibody. Virology 1993, 195, 297-301.
14. Forns, X.; Thimme, R.; Govindarajan, S.; Emerson, S.U.; Purcell, R.H.; Chisari, F.V.; Bukh, J. Hepatitis C virus lacking the hypervariable region 1 of the second envelope protein is infectious and causes acute resolving or persistent infection in chimpanzees. Proc. Natl. Acad. Sci. USA 2000, 97, 13318-13323.
15. Farci, P.; Shimoda, A.; Wong, D.; Cabezon, T.; De Gioannis, D.; Strazzera, A.; Shimizu, Y.; Shapiro, M.; Alter, H.J.; Purcell, R.H. Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc. Natl. Acad. Sci. USA 1996, 93, 15394-15399.
16. Weiner, A.J.; Geysen, H.M.; Christopherson, C.; Hall, J.E.; Mason, T.J.; Saracco, G.; Bonino, F.; Crawford, K.; Marion, C.D.; Crawford, K.A.; Brunetto, M.; Barr, P.J.; Miyamura, T.; McHutchinson, J.; Houghton, M. Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: Potential role in chronic HCV infections. Proc. Natl. Acad. Sci. USA 1992, 89, 3468-3472.
17. Kato, N.; Sekiya, H.; Ootsuyama, Y.; Nakazawa, T.; Hijikata, M.; Ohkoshi, S.; Shimotohno, K. Humoral immune response to hypervariable region 1 of the putative envelope glycoprotein (gp70) of hepatitis C virus. J. Virol. 1993, 67, 3923-3930.
18. Shimizu, Y.K.; Hijikata, M.; Iwamoto, A.; Alter, H.J.; Purcell, R.H.; Yoshikura, H. Neutralizing antibodies against hepatitis C virus and the emergence of neutralization escape mutant viruses. J. Virol. 1994, 68, 1494-1500.
19. Stumpf, M.P.; Pybus, O.G. Genetic diversity and models of viral evolution for the hepatitis C virus. FEMS Microbiol. Lett. 2002, 214, 143-152.
20. Neumann, A.U.; Lam, N.P.; Dahari, H.; Gretch, D.R.; Wiley, T.E.; Layden, T.J.; Perelson, A.S. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy. Science 1998, 282, 103-107.
21. Erickson, A.L.; Kimura, Y.; Igarashi, S.; Eichelberger, J.; Houghton, M.; Sidney, J.; McKinney, D.; Sette, A.; Hughes, A.L.; Walker, C.M. The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes. Immunity 2001, 15, 883-895.
22. Bowen, D.G.; Walker, C.M. Mutational escape from CD8+ T cell immunity: HCV evolution, from chimpanzees to man. J. Exp. Med. 2005, 201, 1709-1714.
23. Uebelhoer, L.; Han, J.H.; Callendret, B.; Mateu, G.; Shoukry, N.H.; Hanson, H.L.; Rice, C.M.; Walker, C.M.; Grakoui, A. Stable cytotoxic T cell escape mutation in hepatitis C virus is linked to maintenance of viral fitness. PLoS. Pathog. 2008, 4, 1-15.
24. von Hahn, T.; Yoon, J.C.; Alter, H.; Rice, C.M.; Rehermann, B.; Balfe, P.; McKeating, J.A. Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. Gastroenterology 2007, 132, 667-678.
25. Puig, M.; Mihalik, K.; Tilton, J.C.; Williams, O.; Merchlinsky, M.; Connors, M.; Feinstone, S.M.; Major, M.E. CD4+ immune escape and subsequent T-cell failure following chimpanzee immunization against hepatitis C virus. Hepatology 2006, 44, 736-745.
26. Folgori, A.; Capone, S.; Ruggeri, L.; Meola, A.; Sporeno, E.; Ercole, B.B.; Pezzanera, M.; Tafi, R.; Arcuri, M.; Fattori, E.; Lahm, A.; Luzzago, A.; Vitelli, A.; Colloca, S.; Cortese, R.; Nicosia, A. A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Nat. Med. 2006, 12, 190-197.
27. Logvinoff, C.; Major, M.E.; Oldach, D.; Heyward, S.; Talal, A.; Balfe, P.; Feinstone, S.M.; Alter, H.; Rice, C.M.; McKeating, J.A. Neutralizing antibody response during acute and chronic hepatitis C virus infection. Proc. Natl. Acad. Sci. USA 2004, 101, 10149-10154.
28. Owsianka, A.; Tarr, A.W.; Juttla, V.S.; Lavillette, D.; Bartosch, B.; Cosset, F.L.; Ball, J.K.; Patel, A.H. Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein. J. Virol. 2005, 79, 11095-11104.
29. Tarr, A.W.; Owsianka, A.M.; Timms, J.M.; McClure, C.P.; Brown, R.J.; Hickling, T.P.; Pietschmann, T.; Bartenschlager, R.; Patel, A.H.; Ball, J.K. Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33. Hepatology 2006, 43, 592-601.
30. Law, M.; Maruyama, T.; Lewis, J.; Giang, E.; Tarr, A.W.; Stamataki, Z.; Gastaminza, P.; Chisari, F.V.; Jones, I.M.; Fox, R.I.; Ball, J.K.; McKeating, J.A.; Kneteman, N.M.; Burton, D.R. Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat. Med. 2008, 14, 25-27.
31. Dahari, H.; Major, M.; Zhang, X.; Mihalik, K.; Rice, C.M.; Perelson, A.S.; Feinstone, S.M.; Neumann, A.U. Mathematical modeling of primary hepatitis C infection: noncytolytic clearance and early blockage of virion production. Gastroenterology 2005, 128, 1056-1066.
32. Major, M.E.; Dahari, H.; Mihalik, K.; Puig, M.; Rice, C.M.; Neumann, A.U.; Feinstone, S.M. Hepatitis C virus kinetics and host responses associated with disease and outcome of infection in chimpanzees. Hepatology 2004, 39, 1709-1720.
33. Prince, A.M.; Pawlotsky, J.M.; Soulier, A.; Tobler, L.; Brotman, B.; Pfahler, W.; Lee, D.H.; Li, L.; Shata, M.T. Hepatitis C virus replication kinetics in chimpanzees with self-limited and chronic infections. J. Viral Hepat. 2004, 11, 236-242.
34. Shoukry, N.H.; Grakoui, A.; Houghton, M.; Chien, D.Y.; Ghrayeb, J.; Reimann, K.A.; Walker, C.M. Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection. J. Exp. Med. 2003, 197, 1645-1655.
35. Thimme, R.; Bukh, J.; Spangenberg, H.C.; Wieland, S.; Pemberton, J.; Steiger, C.; Govindarajan, S.; Purcell, R.H.; Chisari, F.V. Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc. Natl. Acad. Sci. USA 2002, 99, 15661-15668.
36. Farci, P.; Alter, H.J.; Govindarajan, S.; Wong, D.C.; Engle, R.; Lesniewski, R.; Mushahwar, I.K.; Desai, S.M.; Miller, R.H.; Ogata, N.; Purcell, R.H. Lack of protective immunity against reinfection with hepatitis C virus. Science 1992, 258, 140.
37. Prince, A.M.; Brotman, B.; Huima, T.; Pascual, D.; Jaffery, M.; Inchauspe, G. Immunity in hepatitis C infection. J. Infect. Dis. 1992, 165, 438-443.
38. Bassett, S.E.; Guerra, B.; Brasky, K.; Miskovsky, E.; Houghton, M.; Klimpel, G.R.; Lanford, R.E. Protective immune response to hepatitis C virus in chimpanzees rechallenged following clearance of primary infection. Hepatology 2001, 33, 1479-1487.
39. Major, M.E.; Mihalik, K.; Puig, M.; Rehermann, B.; Nascimbeni, M.; Rice, C.M.; Feinstone, S.M. Previously infected and recovered chimpanzees exhibit rapid responses that control hepatitis C virus replication upon rechallenge. J. Virol. 2002, 76, 6586-6595.
40. Mehta, S.H.; Cox, A.; Hoover, D.R.; Wang, X.H.; Mao, Q.; Ray, S.; Strathdee, S.A.; Vlahov, D.; Thomas, D.L. Protection against persistence of hepatitis C. Lancet 2002, 359, 1478-1483.
41. Bukh, J.; Thimme, R.; Meunier, J.C.; Faulk, K.; Spangenberg, H.C.; Chang, K.M.; Satterfield, W.; Chisari, F.V.; Purcell, R.H. Previously infected chimpanzees are not consistently protected against reinfection or persistent infection after reexposure to the identical hepatitis C virus strain. J. Virol. 2008, 82, 8183-8195.
42. Lanford, R.E.; Guerra, B.; Chavez, D.; Bigger, C.; Brasky, K.M.; Wang, X.H.; Ray, S.C.; Thomas, D.L. Cross-genotype immunity to hepatitis C virus. J. Virol. 2004, 78, 1575-1581.
43. Weiner, A.J.; Paliard, X.; Selby, M.J.; Medina-Selby, A.; Coit, D.; Nguyen, S.; Kansopon, J.; Arian, C.L.; Ng, P.; Tucker, J.; Lee, C.T.; Polakos, N.K.; Han, J.; Wong, S.; Lu, H.H.; Rosenberg, S.; Brasky, K.M.; Chien, D.; Kuo, G.; Houghton, M. Intrahepatic genetic inoculation of hepatitis C virus RNA confers cross-protective immunity. J. Virol. 2001, 75, 7142-7148.
44. Diepolder, H.M.; Zachoval, R.; Hoffmann, R.M.; Wierenga, E.A.; Santantonio, T.; Jung, M.C.; Eichenlaub, D.; Pape, G.R. Possible mechanism involving T-lymphocyte response to nonstructural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet 1995, 346, 1006-1007.
45. Diepolder, H.M.; Gerlach, J.T.; Zachoval, R.; Hoffmann, R.M.; Jung, M.C.; Wierenga, E.A.; Scholtz, S.; Santantonio, T.; Houghton, M.; Southwood, S.; Sette, A.; Pape, G.R. Immunodominant CD4+ T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection. J. Virol. 1997, 71, 6011-6019.
46. Gerlach, J.T.; Diepolder, H.M.; Jung, M.C.; Gruener, N.H.; Schraut, W.W.; Zachoval, R.; Hoffmann, R.; Schirren, C.A.; Santantonio, T.; Pape, G.R. Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C. Gastroenterology 1999, 117, 933-941.
47. Wertheimer, A.M.; Miner, C.; Lewinsohn, D.M.; Sasaki, A.W.; Kaufman, E.; Rosen, H.R. Novel CD4+ and CD8+ T-cell determinants within the NS3 protein in subjects with spontaneously resolved HCV infection. Hepatology 2003, 37, 577-589.
48. Lechner, F.; Wong, D.K.; Dunbar, P.R.; Chapman, R.; Chung, R.T.; Dohrenwend, P.; Robbins, G.; Phillips, R.; Klenerman, P.; Walker, B.D. Analysis of successful immune responses in persons infected with hepatitis C virus. J. Exp. Med. 2000, 191, 1499-1512.
49. Thimme, R.; Oldach, D.; Chang, K.M.; Steiger, C.; Ray, S.C.; Chisari, F.V. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J. Exp. Med. 2001, 194, 1395-1406.
50. Bowen, D.G.; Walker, C.M. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 2005, 436, 946-952.
51. Takaki, A.; Wiese, M.; Maertens, G.; Depla, E.; Seifert, U.; Liebetrau, A.; Miller, J.L.; Manns, M.P.; Rehermann, B. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat. Med. 2000, 6, 578-582.
52. Grakoui, A.; Shoukry, N.H.; Woollard, D.J.; Han, J.H.; Hanson, H.L.; Ghrayeb, J.; Murthy, K.K.; Rice, C.M.; Walker, C.M. HCV persistence and immune evasion in the absence of memory T cell help. Science 2003, 302, 659-662.
53. Nascimbeni, M.; Mizukoshi, E.; Bosmann, M.; Major, M.E.; Mihalik, K.; Rice, C.M.; Feinstone, S.M.; Rehermann, B. Kinetics of CD4+ and CD8+ memory T-cell responses during hepatitis C virus rechallenge of previously recovered chimpanzees. J. Virol. 2003, 77, 4781-4793.
54. Bartosch, B.; Dubuisson, J.; Cosset, F.L. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J. Exp. Med. 2003, 197, 633-642.
55. Hsu, M.; Zhang, J.; Flint, M.; Logvinoff, C.; Cheng-Mayer, C.; Rice, C.M.; McKeating, J.A. Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc. Natl. Acad. Sci. USA 2003, 100, 7271-7276.
56. Wakita, T.; Pietschmann, T.; Kato, T.; Date, T.; Miyamoto, M.; Zhao, Z.; Murthy, K.; Habermann, A.; Krausslich, H.G.; Mizokami, M.; Bartenschlager, R.; Liang, T.J. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 2005, 11, 791-796.
57. Lindenbach, B.D.; Evans, M.J.; Syder, A.J.; Wolk, B.; Tellinghuisen, T.L.; Liu, C.C.; Maruyama, T.; Hynes, R.O.; Burton, D.R.; McKeating, J.A.; Rice, C.M. Complete replication of hepatitis C virus in cell culture. Science 2005, 309, 623-626.
58. Kato, T.; Matsumura, T.; Heller, T.; SAITO, S.; Sapp, R.K.; Murthy, K.; Wakita, T.; Liang, T.J. Production of infectious hepatitis C virus of various genotypes in cell cultures. J. Virol. 2007, 81, 4405-4411.
59. Gottwein, J.M.; Scheel, T.K.; Hoegh, A.M.; Lademann, J.B.; Eugen-Olsen, J.; Lisby, G.; Bukh, J. Robust hepatitis C genotype 3a cell culture releasing adapted intergenotypic 3a/2a (S52/JFH1) viruses. Gastroenterology 2007, 133, 1614-1626.
60. Scheel, T.K.; Gottwein, J.M.; Jensen, T.B.; Prentoe, J.C.; Hoegh, A.M.; Alter, H.J.; Eugen-Olsen, J.; Bukh, J. Development of JFH1-based cell culture systems for hepatitis C virus genotype 4a and evidence for cross-genotype neutralization. Proc. Natl. Acad. Sci. USA 2008, 105, 997-1002.
61. Jensen, T.B.; Gottwein, J.M.; Scheel, T.K.; Hoegh, A.M.; Eugen-Olsen, J.; Bukh, J. Highly efficient JFH1-based cell-culture system for hepatitis C virus genotype 5a: failure of homologous neutralizing-antibody treatment to control infection. J. Infect. Dis. 2008, 198, 1756-1765.
62. Bartosch, B.; Bukh, J.; Meunier, J.C.; Granier, C.; Engle, R.E.; Blackwelder, W.C.; Emerson, S.U.; Cosset, F.L.; Purcell, R.H. In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes. Proc. Natl. Acad. Sci. USA 2003, 100, 14199-14204.
63. Pestka, J.M.; Zeisel, M.B.; Blaser, E.; Schurmann, P.; Bartosch, B.; Cosset, F.L.; Patel, A.H.; Meisel, H.; Baumert, J.; Viazov, S.; Rispeter, K.; Blum, H.E.; Roggendorf, M.; Baumert, T.F. Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc. Natl. Acad. Sci. USA 2007, 104, 6025-6030.
64. Lavillette, D.; Morice, Y.; Germanidis, G.; Donot, P.; Soulier, A.; Pagkalos, E.; Sakellariou, G.; Intrator, L.; Bartosch, B.; Pawlotsky, J.M.; Cosset, F.L. Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection. J. Virol. 2005, 79, 6023-6034.
65. Dowd, K.A.; Netski, D.M.; Wang, X.H.; Cox, A.L.; Ray, S.C. Selection pressure from neutralizing antibodies drives sequence evolution during acute infection with hepatitis C virus. Gastroenterology 2009, 136, 2377-2386.
66. Meunier, J.C.; Engle, R.E.; Faulk, K.; Zhao, M.; Bartosch, B.; Alter, H.; Emerson, S.U.; Cosset, F.L.; Purcell, R.H.; Bukh, J. Evidence for cross-genotype neutralization of hepatitis C virus pseudo-particles and enhancement of infectivity by apolipoprotein C1. Proc. Natl. Acad. Sci. USA 2005, 102, 4560-4565.
67. Farci, P.; Alter, H.J.; Wong, D.C.; Miller, R.H.; Govindarajan, S.; Engle, R.; Shapiro, M.; Purcell, R.H. Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. Proc. Natl. Acad. Sci. USA 1994, 91, 7792-7796.
68. Krawczynski, K.; Alter, M.J.; Tankersley, D.L.; Beach, M.; Robertson, B.H.; Lambert, S.; Kuo, G.; Spelbring, J.E.; Meeks, E.; Sinha, S.; Carson, D.A. Effect of immune globulin on the prevention of experimental hepatitis C virus infection. J. Infect. Dis. 1996, 173, 822-828.
69. Yu, M.Y.; Bartosch, B.; Zhang, P.; Guo, Z.P.; Renzi, P.M.; Shen, L.M.; Granier, C.; Feinstone, S.M.; Cosset, F.L.; Purcell, R.H. Neutralizing antibodies to hepatitis C virus (HCV) in immune globulins derived from anti-HCV-positive plasma. Proc. Natl. Acad. Sci. USA 2004, 101, 7705-7710.
70. Youn, J.W.; Hu, Y.W.; Tricoche, N.; Pfahler, W.; Shata, M.T.; Dreux, M.; Cosset, F.L.; Folgori, A.; Lee, D.H.; Brotman, B.; Prince, A.M. Evidence for protection against chronic hepatitis C virus infection in chimpanzees by immunization with replicating recombinant vaccinia virus. J. Virol. 2008, 82, 10896-10905.
71. Zubkova, I.; Choi, Y.H.; Chang, E.; Pirollo, K.; Uren, T.; Watanabe, H.; Wells, F.; Kachko, A.; Krawczynski, K.; Major, M.E. T-cell vaccines that elicit effective immune responses against HCV in chimpanzees may create greater immune pressure for viral mutation. Vaccine 2009, 27, 2594-2602.
72. Choo, Q.L.; Kuo, G.; Ralston, R.; Weiner, A.; Chien, D.; Van Nest, G.; Han, J.; Berger, K.; Thudium, K.; Kuo, C. Vaccination of chimpanzees against infection by the hepatitis C virus. Proc. Natl. Acad. Sci. USA 1994, 91, 1294-1298.
73. Coates, S.; Choo, Q. L.; Kuo, G.; Crawford, K.; Dong, C.; Wininger, M.; Weiner, A. J.; Berger, K.; Wong, S.; Ralston, R.; Morandi, M.; Pileri, P.; Rosa, D.; Muchmore, E.; Mahony, J.; Brasky, K.M.; Purceli, R.H.; Abrignani, S.; Houghton, M. Protection of Chimpanzees against Heterologous 1a Viral Challenge using a gpE1/gpE2 Heterodimer Vaccine. In Proceedings of the 11th International Symposium on Viral Hepatitis and Liver Disease, Sydney, Australia, 6-10 April, 2003; Jilbert, A.R., Grgacic, E., Vickery, K., Burrell, C.J., Cossart, Y.E., Eds; Australian Center for Hepatitis Virology: Sydney, 2004; pp. 118-123.
74. Forns, X.; Payette, P.J.; Ma, X.; Satterfield, W.; Eder, G.; Mushahwar, I.K.; Govindarajan, S.; Davis, H.L.; Emerson, S.U.; Purcell, R.H.; Bukh, J. Vaccination of chimpanzees with plasmid DNA encoding the hepatitis C virus (HCV) envelope E2 protein modified the infection after challenge with homologous monoclonal HCV. Hepatology 2000, 32, 618-625.
75. Elmowalid, G.A.; Qiao, M.; Jeong, S.H.; Borg, B.B.; Baumert, T.F.; Sapp, R.K.; Hu, Z.; Murthy, K.; Liang, T.J. Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees. Proc. Natl. Acad. Sci. U SA 2007, 104, 8427-8432.
76. Puig, M.; Major, M.E.; Mihalik, K.; Yu, M.Y.; Feinstone, S.M. Immunization of chimpanzees with an envelope protein-based vaccine enhances specific humoral and cellular immune responses that delay hepatitis C virus infection. Vaccine 2004, 22, 991-1000.
77. Rollier, C.; Depla, E.; Drexhage, J.A.; Verschoor, E.J.; Verstrepen, B.E.; Fatmi, A.; Brinster, C.; Fournillier, A.; Whelan, J.A.; Whelan, M.; Jacobs, D.; Maertens, G.; Inchauspe, G.; Heeney, J.L. Control of heterologous hepatitis C virus infection in chimpanzees is associated with the quality of vaccine-induced peripheral T-helper immune response. J. Virol. 2004, 78, 187-196.
78. Youn, J.W.; Park, S.H.; Lavillette, D.; Cosset, F.L.; Yang, S.H.; Lee, C.G.; Jin, H.T.; Kim, C.M.; Shata, M.T.; Lee, D.H.; Pfahler, W.; Prince, A.M.; Sung, Y.C. Sustained E2 antibody response correlates with reduced peak viremia after hepatitis C virus infection in the chimpanzee. Hepatology 2005, 42, 1429-1436.
79. Rollier, C.S.; Paranhos-Baccala, G.; Verschoor, E.J.; Verstrepen, B.E.; Drexhage, J.A.; Fagrouch, Z.; Berland, J.L.; Komurian-Pradel, F.; Duverger, B.; Himoudi, N.; Staib, C.; Meyr, M.; Whelan, M.; Whelan, J.A.; Adams, V.C.; Larrea, E.; Riezu, J.I.; Lasarte, J.J.; Bartosch, B.; Cosset, F.L.; Spaan, W.J.; Diepolder, H.M.; Pape, G.R.; Sutter, G.; Inchauspe, G.; Heeney, J.L. Vaccine-induced early control of hepatitis C virus infection in chimpanzees fails to impact on hepatic PD-1 and chronicity. Hepatology 2007, 45, 602-613.
80. Zhu, Y.D.; Heath, J.; Collins, J.; Greene, T.; Antipa, L.; Rota, P.; Bellini, W.; McChesney, M. Experimental measles. II. Infection and immunity in the rhesus macaque. Virology 1997, 233, 85-92.
81. Betts, R.F.; Treanor, J.J. Approaches to improved influenza vaccination. Vaccine 2000, 18, 1690-1695.
82. Onorato, I.M.; Modlin, J.F.; McBean, A.M.; Thoms, M.L.; Losonsky, G.A.; Bernier, R.H. Mucosal immunity induced by enhance-potency inactivated and oral polio vaccines. J. Infect. Dis. 1991, 163, 1-6.
83. Ross, R.S.; Viazov, S.O.; Hoffmann, S.; Roggendorf, M. Performance characteristics of a transcription-mediated nucleic acid amplification assay for qualitative detection of hepatitis C virus RNA. J. Clin. Lab Anal. 2001, 15, 308-313.
84. Werzberger, A.; Mensch, B.; Kuter, B.; Brown, L.; Lewis, J.; Sitrin, R.; Miller, W.; Shouval, D.; Wiens, B.; Calandra, G. A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. N. Engl. J. Med. 1992, 327, 453-457.
85. Innis, B.L.; Snitbhan, R.; Kunasol, P.; Laorakpongse, T.; Poopatanakool, W.; Kozik, C.A.; Suntayakorn, S.; Suknuntapong, T.; Safary, A.; Tang, D.B. Protection against hepatitis A by an inactivated vaccine. JAMA 1994, 271, 1328-1334.
86. Zuckerman, A.J. Immunization against hepatitis B. Br. Med. Bull. 1990, 46, 383-398.
87. Koutsky, L.A.; Ault, K.A.; Wheeler, C.M.; Brown, D.R.; Barr, E.; Alvarez, F.B. Chiacchierini, L.M.; Jansen, K.U. A controlled trial of a human papillomavirus type 16 vaccine. N. Engl. J. Med. 2002, 347, 1645-1651.
88. Alter, H.J.; Seeff, L.B. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin. Liver Dis. 2000, 20, 17-35.
89. Seeff, L.B. Natural history of chronic hepatitis C. Hepatology 2002, 36, S35-S46.
90. Zhang, P.; Zhong, L.; Struble, E.B.; Watanabe, H.; Kachko, A.; Mihalik, K.; Virata-Theimer, M.L.; Alter, H.J.; Feinstone, S.; Major, M. Depletion of interfering antibodies in chronic hepatitis C patients and vaccinated chimpanzees reveals broad cross-genotype neutralizing activity. Proc. Natl. Acad. Sci. USA 2009, 106, 7537-7541.
91. Zhang, P.; Wu, C.G.; Mihalik, K.; Virata-Theimer, M.L.; Yu, M.Y.; Alter, H.J.; Feinstone, S.M. Hepatitis C virus epitope-specific neutralizing antibodies in Igs prepared from human plasma. Proc. Natl. Acad. Sci. USA 2007, 104, 8449-8454.
92. Seder, R.A.; Ahmed, R. Similarities and differences in CD4+ and CD8+ effector and memory T cell generation. Nat. Immunol. 2003, 4, 835-842.
93. Harari, A.; Bart, P.A.; Stohr, W.; Tapia, G.; Garcia, M.; Medjitna-Rais, E.; Burnet, S.; Cellerai, C.; Erlwein, O.; Barber, T.; Moog, C.; Liljestrom, P.; Wagner, R.; Wolf, H.; Kraehenbuhl, J.P.; Esteban, M.; Heeney, J.; Frachette, M.J.; Tartaglia, J.; McCormack, S.; Babiker, A.; Weber, J.; Pantaleo, G. An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J. Exp. Med. 2008, 205, 63-77.
94. Thacker, E.E.; Timares, L.; Matthews, Q.L. Strategies to overcome host immunity to adenovirus vectors in vaccine development. Exp. Rev. Vaccines. 2009, 8, 761-777.
95. Abraham, J.D.; Himoudi, N.; Kien, F.; Berland, J.L.; Codran, A.; Bartosch, B.; Baumert, T.; Paranhos-Baccala, G.; Schuster, C.; Inchauspe, G.; Kieny, M.P. Comparative immunogenicity analysis of modified vaccinia Ankara vectors expressing native or modified forms of hepatitis C virus E1 and E2 glycoproteins. Vaccine 2004, 22, 3917-3928.
96. Earl, P.L.; Americo, J.L.; Wyatt, L.S.; Espenshade, O.; Bassler, J.; Gong, K.; Lin, S.; Peters, E.; Rhodes, L., Jr.; Spano, Y.E.; Silvera, P.M.; Moss, B. Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus. Proc. Natl. Acad. Sci. USA 2008, 105, 10889-10894.
97. Brinster, C.; Chen, M.; Boucreux, D.; Paranhos-Baccala, G.; Liljestrom, P.; Lemmonier, F.; Inchauspe, G. Hepatitis C virus non-structural protein 3-specific cellular immune responses following single or combined immunization with DNA or recombinant Semliki Forest virus particles. J. Gen. Virol. 2002, 83, 369-381.
98. Lin, Y.; Kwon, T.; Polo, J.; Zhu, Y.F.; Coates, S.; Crawford, K.; Dong, C.; Wininger, M.; Hall, J.; Selby, M.; Coit, D.; Medina-Selby, A.; McCoin, C.; Ng, P.; Drane, D.; Chien, D.; Han, J.; Vajdy, M.; Houghton, M. Induction of broad CD4+ and CD8+ T-cell responses and crossneutralizing antibodies against hepatitis C virus by vaccination with Th1-adjuvanted polypeptides followed by defective alphaviral particles expressing envelope glycoproteins gpE1 and gpE2 and nonstructural proteins 3, 4, and 5. J. Virol. 2008, 82, 7492-7503.
99. Xiong, C.; Levis, R.; Shen, P.; Schlesinger, S.; Rice, C.M.; Huang, H.V. Sindbis virus: an efficient, broad host range vector for gene expression in animal cells. Science 1989, 243, 1188-1191.
100. Leitner, W.W.; Hwang, L.N.; deVeer, M.J.; Zhou, A.; Silverman, R.H.; Williams, B.R.; Dubensky, T.W.; Ying, H.; Restifo, N.P. Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways. Nat. Med. 2003, 9, 33-39.
101. Perri, S.; Greer, C.E.; Thudium, K.; Doe, B.; Legg, H.; Liu, H.; Romero, R.E.; Tang, Z.; Bin, Q.; Dubensky, T.W., Jr.; Vajdy, M.; Otten, G.R.; Polo, J.M. An alphavirus replicon particle chimera derived from venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector. J. Virol. 2003, 77, 10394-10403.
102. Martin, P.; Simon, B.; Lone, Y.C.; Chatel, L.; Barry, R.; Inchauspe, G.; Fournillier, A. A vectorbased minigene vaccine approach results in strong induction of T-cell responses specific of hepatitis C virus. Vaccine 2008, 26, 2471-2481.
103. Jaeckel, E.; Cornberg, M.; Wedemeyer, H.; Santantonio, T.; Mayer, J.; Zankel, M.; Pastore, G.; Dietrich, M.; Trautwein, C.; Manns, M.P. Treatment of acute hepatitis C with interferon alfa-2b. N. Engl. J. Med. 2001, 345, 1452-1457.
104. Lohmann, V.; Korner, F.; Koch, J.; Herian, U.; Theilmann, L.; Bartenschlager, R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999, 285, 110-113.
105. Blight, K.J.; Kolykhalov, A.A.; Rice, C.M. Efficient initiation of HCV RNA replication in cell culture. Science 2000, 290, 1972-1974.
106. Yutani, S.; Yamada, A.; Yoshida, K.; Takao, Y.; Tamura, M.; Komatsu, N.; Ide, T.; Tanaka, M.; Sata, M.; Itoh, K. Phase I clinical study of a personalized peptide vaccination for patients infected with hepatitis C virus (HCV) 1b who failed to respond to interferon-based therapy. Vaccine 2007, 25, 7429-7435.
107. Klade, C.S.; Wedemeyer, H.; Berg, T.; Hinrichsen, H.; Cholewinska, G.; Zeuzem, S.; Blum, H.; Buschle, M.; Jelovcan, S.; Buerger, V.; Tauber, E.; Frisch, J.; Manns, M.P. Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41. Gastroenterology 2008, 134, 1385-1395.
108. Fournillier, A.; Gerossier, E.; Evlache, A.; Martin, P.; Bain, C.; Schmidt, D.; Silvestre N; Julien, M.; Habersetzer, F.; Zarski, J.; Leroy, V.; Maynard-Muet, M.; Trepo, C.; Agathon, D.; Bonnefoy, J.; Burtin, B.; Honnet, G.; Inchauspe, G. Therapeutic vaccination against HCV: pre-clinical and clinical evaluation of a novel MVA-based vaccine. In 15th International Symposium on Hepatitis C and Related Viruses, San Antonio, Texas, USA, 5 October 2008.
109. Nevens, F.; Roskams, T.; Van Vlierberghe, H.; Horsmans, Y.; Sprengers, D.; Elewaut, A.; Desmet, V.; Leroux-Roels, G.; Quinaux, E.; Depla, E.; Dincq, S.; Vander, S.C.; Maertens, G.; Hulstaert, F. A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients with chronic hepatitis C. Hepatology 2003, 38, 1289-1296.
110. Alvarez-Lajonchere, L.; Shoukry, N.H.; Gra, B.; Amador-Canizares, Y.; Helle, F.; Bedard, N.; Guerra, I.; Drouin, C.; Dubuisson, J.; Gonzalez-Horta, E.E.; Martinez, G.; Marante, J.; Cinza, Z.; Castellanos, M.; Duenas-Carrera, S. Immunogenicity of CIGB-230, a therapeutic DNA vaccine preparation, in HCV-chronically infected individuals in a Phase I clinical trial. J. Viral Hepat. 2009, 16, 156-167.
111. Batdelger, D.; Dandii, D.; Jirathitikal, V.; Bourinbaiar, A.S. Open-label trial of therapeutic immunization with oral V-5 Immunitor (V5) vaccine in patients with chronic hepatitis C. Vaccine 2008, 26, 2733-2737.
112. Wedemeyer, H.; Schuller, E.; Schlaphoff, V.; Stauber, R.E.; Wiegand, J.; Schiefke, I.; Firbas, C.; Jilma, B.; Thursz, M.; Zeuzem, S.; Hofmann, W.P.; Hinrichsen, H.; Tauber, E.; Manns, M.P.; Klade, C.S. Therapeutic vaccine IC41 as late add-on to standard treatment in patients with chronic hepatitis C. Vaccine 2009, in Press.
113. Chua, B.Y.; Eriksson, E.M.; Brown, L.E.; Zeng, W.; Gowans, E.J.; Torresi, J.; Jackson, D.C. A self-adjuvanting lipopeptide-based vaccine candidate for the treatment of hepatitis C virus infection. Vaccine 2008, 26, 4866-4875.
114. Thammanichanond, D.; Moneer, S.; Yotnda, P.; Aitken, C.; Earnest-Silveira, L.; Jackson, D.; Hellard, M.; McCluskey, J.; Torresi, J.; Bharadwaj, M. Fiber-modified recombinant adenoviral constructs encoding hepatitis C virus proteins induce potent HCV-specific T cell response. Clin. Immunol. 2008, 128, 329-339.
115. Leroux-Roels, G.; Depla, E.; Hulstaert, F.; Tobback, L.; Dincq, S.; Desmet, J.; Desombere, I.; Maertens, G. A candidate vaccine based on the hepatitis C E1 protein: tolerability and immunogenicity in healthy volunteers. Vaccine 2004, 22, 3080-3086.
116. Leroux-Roels, G.; Batens, A.H.; Desombere, I.; Van Den, S.B.; Vander, S.C.; Maertens, G.; Hulstaert, F. Immunogenicity and tolerability of intradermal administration of an HCV E1-based vaccine candidate in healthy volunteers and patients with resolved or ongoing chronic HCV infection. Hum. Vaccin. 2005, 1, 61-65.
117. Polakos, N.K.; Drane, D.; Cox, J.; Ng, P.; Selby, M.J.; Chien, D.; O'Hagan, D.T.; Houghton, M.; Paliard, X. Characterization of hepatitis C virus core-specific immune responses primed in rhesus macaques by a nonclassical ISCOM vaccine. J. Immunol. 2001, 166, 3589-3598.
118. Pearse, M.J.; Drane, D. ISCOMATRIX adjuvant for antigen delivery. Adv. Drug Deliv. Rev. 2005, 57, 465-474.
119. Drane, D.; Maraskovsky, E.; Gibson, R.; Mitchell, S.; Barnden, M.; Moskwa, A.; Shaw, D.; Gervase, B.; Coates, S.; Houghton, M.; Basser, R. Priming of CD4(+) and CD8(+) T cell responses using a HCV core ISCOMATRIX(TM) vaccine: A phase I study in healthy volunteers. Hum. Vaccin. 2009, 5, 151-157.
120. Fournillier, A.; Gerossier, E.; Evlashev, A.; Schmitt, D.; Simon, B.; Chatel, L.; Martin, P.; Silvestre, N.; Balloul, J.M.; Barry, R.; Inchauspe, G. An accelerated vaccine schedule with a poly-antigenic hepatitis C virus MVA-based candidate vaccine induces potent, long lasting and in vivo cross-reactive T cell responses. Vaccine 2007, 25, 7339-7353.
121. Inchauspe, G.; Michel, M.L. Vaccines and immunotherapies against hepatitis B and hepatitis C viruses. J. Viral Hepat. 2007, 14 Suppl. 1, 97-103.